Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Bruce Leicher sold 802 shares of the stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $15.20, for a total transaction of $12,190.40. Following the completion of the sale, the senior vice president now directly owns 174,064 shares in the company, valued at $2,645,772.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Bruce Leicher also recently made the following trade(s):

  • On Thursday, August 10th, Bruce Leicher sold 350 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $16.60, for a total transaction of $5,810.00.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) traded down 1.097% during trading on Friday, hitting $15.775. 111,949 shares of the stock were exchanged. The company’s market cap is $1.17 billion. The stock’s 50 day moving average price is $16.40 and its 200-day moving average price is $15.62. Momenta Pharmaceuticals, Inc. has a one year low of $10.75 and a one year high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.50). The company had revenue of $23.57 million for the quarter, compared to analyst estimates of $24.64 million. Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The business’s quarterly revenue was down 10.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.31) earnings per share. On average, analysts predict that Momenta Pharmaceuticals, Inc. will post ($1.09) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Bruce Leicher Sells 802 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/bruce-leicher-sells-802-shares-of-momenta-pharmaceuticals-inc-mnta-stock/1522658.html.

MNTA has been the topic of a number of recent analyst reports. Stifel Nicolaus reissued a “buy” rating and issued a $26.00 price objective on shares of Momenta Pharmaceuticals in a research report on Thursday, August 3rd. BidaskClub raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Barclays PLC lowered shares of Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $20.00 to $17.00 in a research report on Monday, May 22nd. Cowen and Company reissued a “hold” rating and issued a $15.00 price objective on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 3rd. Finally, Aegis reissued a “hold” rating and issued a $17.00 price objective on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 3rd. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $16.63.

Several hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. raised its stake in Momenta Pharmaceuticals by 14.9% in the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock worth $109,000 after buying an additional 834 shares in the last quarter. Tortoise Investment Management LLC purchased a new stake in Momenta Pharmaceuticals during the second quarter worth about $114,000. Pinebridge Investments L.P. raised its stake in Momenta Pharmaceuticals by 4.3% in the second quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock worth $149,000 after buying an additional 363 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Momenta Pharmaceuticals during the first quarter worth about $158,000. Finally, BNP Paribas Arbitrage SA raised its stake in Momenta Pharmaceuticals by 13.3% in the first quarter. BNP Paribas Arbitrage SA now owns 13,393 shares of the biotechnology company’s stock worth $179,000 after buying an additional 1,570 shares in the last quarter. Institutional investors own 87.15% of the company’s stock.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.